Oncology Resources

Oncology

WEBSITE

HER2Know

HER2 IHC Testing in Solid Tumors

VIDEO

Rethinking ESR1 Testing in HR+/HER2− Advanced Breast Cancer

This program discusses:

• The clinical implications of ESR1 mutations in HR+/HER2− advanced breast cancer
• Limitations of current ESR1 testing strategies and rationale for investigational approaches
• How an investigational strategy may help detect resistance before clinical progression

VIDEO

Endocrine Therapy in HR+/HER2− Advanced Breast Cancer: A Deeper Look at a 50-Year Evolution

This program discusses:

• The evolution of endocrine therapies for HR+/HER2− advanced breast cancer
• How the current standards of care work to treat patients
• How the treatment landscape may continue to evolve to address existing unmet needs

VIDEO

Exploring the patient journey and unmet needs in eTNBC

Although most patients with TNBC are diagnosed in the early-stage curative setting, significant unmet needs remain despite advancements in targeted treatments. It is essential to raise HCP awareness around these patients, who require more efficacious and tolerable therapy options compared to the current standard of care. Additionally, there is growing recognition of the need to enhance patient-centred care beyond treatment, addressing psychological well-being, social support and survivorship as integral components in the management of TNBC.

Explore the patient journey and unmet needs for patients with eTNBC with insights from Matteo Lambertini, an Associate Professor and Consultant in Medical Oncology, whose research specialises in breast cancer care, with a particular focus on the management of breast cancer and fertility preservation.

VIDEO

TNBC Unmet Need Campaign

Despite a number of exciting targeted-treatment advances in TNBC over the last decade, the majority of patients with mTNBC do not express the biomarkers necessary to benefit from these therapies, and even those who do may still be ineligible for treatment. Enhancing healthcare professionals' awareness of these patients' needs is essential as we strive for more effective and tolerable treatmentoptions.

Explore the unmet needs for patients with first-line mTNBC treatment with insights from Paolo Tarantino, a breast medical oncologist and clinical researcher, whose research focusses on the HER2 oncoprotein and the development of novel therapies that target multiple subtypes, including TNBC.